

Special Issue

Prostate Cancer Therapy: Supporting Strategies and Management Options

Message from the Guest Editors

Prostate cancer (PCa) stands as one of the most prevalent cancers affecting men globally. As with any malignancy, early detection, pre-treatment preparation and prehabilitation, and effective disease management are paramount in determining favorable patient outcomes. We are excited to announce our upcoming Special Issue, aiming to provide a comprehensive overview of the current landscape of PCa treatment. It will particularly focus on supportive measures and diverse management options, serving as a vital resource for researchers, practitioners and clinicians in this field. To ensure that this Special Issue becomes a comprehensive and authoritative resource, we are inviting submissions of original research and reviews. We are eager to receive your contributions and await your insightful research on PCa therapy and supportive strategies. Your expertise and dedication are crucial in advancing our collective knowledge in this critical area of medicine. We sincerely appreciate your commitment to advancing PCa research and patient care.

Guest Editors

Dr. Ingmar Wolff

Department of Urology, University Medicine Greifswald, 17475 Greifswald, Germany

Prof. Dr. Matthias May

Department of Urology, St. Elisabeth Hospital Straubing, 94315 Straubing, Germany

Deadline for manuscript submissions

closed (31 July 2025)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/190686

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)